Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Under what circumstances would you use pasireotide in the management of insulinoma-associated hypoglycemia?
Vega-Beyhart, et al., PMID 40165498
Related Questions
How should diabetic retinopathy surveillance be adjusted for patients starting GLP-1 agonists?
Would you consider starting short-term metformin in an otherwise healthy patient who is beginning high-dose glucocorticoids to prevent glucocorticoid-induced insulin resistance?
Would you recommend the use of an ACE inhibitor to patients with Type 1 diabetes mellitus who are normotensive but have persistent moderate proteinuria?
How has the use of CGMs informed or improved your management of patients with pre diabetes or diabetes not on insulin?
What dietary modifications do you recommend for the management of type 2 diabetes, considering the benefits of Mediterranean, plant-based, low-carbohydrate, and ketogenic diets?
What factors do you consider when deciding what type of glucagon preparation to prescribe for rescue hypoglycemia in patients with diabetes on insulin therapy?
What is the preferred first-line non-insulin agent in patients with ketosis-prone diabetes during "remission" and evidence of preserved beta cell function?
What is your approach to the use of GLP-1 agonists in older adults with diabetes with or at risk of sarcopenia?
How would you advise medical oncologists who recommend checkpoint inhibitors for a patient with baseline type 1 diabetes?
Is the combination of SGLT2i and GLP 1 R agonist therapy contraindicated in patients who develop an episode of euglycemic DKA?
